Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限 公 司 (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號: 8622 ANNUAL REPORT 年報 2020 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors shoul ...

Revenue Performance - For the nine months ended September 30, 2020, the Group experienced a significant decrease in revenue from male fertility IVD reagent products, primarily due to the COVID-19 epidemic, which led to a halt in production for approximately five weeks [16]. - Revenue for the nine months ended 30 September 2020 decreased by approximately RMB4.3 million, or 23.4%, to approximately RMB14.1 million compared to RMB18.4 million for the same period last year [27]. - Sales of male fertility IVD reagents accounted for approximately 76.5% of total revenue, with revenue from this segment decreasing by approximately RMB3.7 million, or 25.7%, to approximately RMB10.8 million [32]. - Revenue for the three months ended September 30, 2020, was RMB 6,891,000, a slight increase of 1.7% compared to RMB 6,776,000 for the same period in 2019 [153]. - Total revenue for the three months ended September 30, 2020, was RMB 6,891,000, a slight increase from RMB 6,776,000 in the same period of 2019, representing a growth of 1.7% [170]. - Total revenue for the nine months ended September 30, 2020, was RMB 14,099,000, down from RMB 18,412,000 in the same period of 2019, a decrease of 23.5% [170]. Profit and Loss - For the nine months ended 30 September 2020, the company recorded a loss attributable to owners of approximately RMB 6.6 million, compared to a profit of approximately RMB 1.7 million for the same period in 2019, representing a significant decrease due to reduced revenue [50][53]. - The company reported a loss attributable to owners of RMB 6,602,000 for the nine months ended September 30, 2020, compared to a profit of RMB 1,721,000 in the same period of 2019 [153]. - The basic and diluted loss per share for the nine months ended September 30, 2020, was RMB (1.64) cents, compared to earnings of RMB 0.43 cents in the same period of 2019 [153]. - For the three months ended September 30, 2020, the company reported a loss attributable to owners of RMB 495,000 compared to a profit of RMB 1,498,000 in the same period of 2019, representing a significant decline [196]. Expenses - Gross profit for the nine months ended 30 September 2020 was approximately RMB9.9 million, a decrease of approximately RMB3.3 million, or 25.2%, from RMB13.2 million for the same period last year [33]. - Administrative expenses increased by approximately RMB3.3 million, or 51.9%, from approximately RMB6.3 million to approximately RMB9.6 million, primarily due to non-cash share option expenses and other operational costs [43]. - Research and development expenses increased by approximately RMB 351,000 or 30.3%, from RMB 1.2 million for the nine months ended 30 September 2019 to RMB 1.5 million for the same period in 2020, mainly due to the purchase of raw materials and equipment for product application of chemiluminescence technology [49][52]. - Selling and distribution expenses for the three months ended September 30, 2020, were RMB 1,797,000, an increase of 7.4% compared to RMB 1,673,000 in the same period of 2019 [153]. Impairment and Receivables - Impairment losses on trade receivables were approximately RMB744,000 for the nine months ended 30 September 2020, compared to a reversal of impairment losses of approximately RMB534,000 for the same period in 2019 [41]. - Trade receivables impairment loss for the nine months ended 30 September 2020 was approximately RMB 744,000, an increase from RMB 534,000 for the same period in 2019, primarily due to the deterioration of customers' repayment ability since the outbreak of the pandemic [45]. - Impairment losses on trade receivables for the nine months ended September 30, 2020, were RMB 744,000, a significant increase from a loss of RMB 511,000 in the same period of 2019 [183]. Government Support and Other Income - Other income increased by approximately RMB366,000, or 185.8%, to approximately RMB563,000 due to grants received from the Hong Kong Government under the Employment Support Scheme [35]. - Government grants received in Q3 2020 amounted to RMB 373,000, significantly higher than RMB 21,000 in Q3 2019 [179]. - The company reported total other income of RMB 444,000 for Q3 2020, compared to RMB 81,000 in Q3 2019, marking an increase of 448.1% [179]. Corporate Governance and Compliance - The Company has adopted and complied with the Corporate Governance Code during the nine months ended September 30, 2020 [134]. - The Board is committed to high corporate governance standards to safeguard shareholder interests and enhance corporate value [133]. - The Audit Committee has reviewed the unaudited condensed consolidated financial results for the nine months ended September 30, 2020, and confirmed compliance with applicable accounting standards and GEM Listing Rules [149]. - The Company has confirmed that all Directors complied with the required standards for securities transactions during the relevant period [142]. Share Capital and Options - As of 30 September 2020, the company's issued share capital was HK$4 million, with 400,000,000 shares issued at HK$0.01 each [71]. - The company granted a total of 26,008,000 share options on 9 April 2020, with an exercise price of HK$0.125 per share, all options are exercisable until 8 April 2030 [58][60]. - The weighted average number of ordinary shares in issue for the purpose of basic earnings per share remained constant at 400,000 shares for both the current and previous periods [196]. Future Outlook and Strategy - The Group aims to enhance product competitiveness through increased research and development and market promotion efforts [21]. - The establishment of a laboratory in Beijing is in progress to support research and development in assisted reproductive treatment technologies [25]. - The Group will continue to employ prudent treasury policies to maintain strong liquidity ratios for future growth opportunities [78].

Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限 公 司 (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號: 8622 2020 Interim Report 中期業績報告 Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限 公 司 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other com ...

Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限 公 司 (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號: 8622 2020 First Quarterly Report 第一季業績報告 Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限 公 司 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than ...

Revenue Performance - Revenue from the PRC male fertility IVD reagent market amounted to approximately RMB19.4 million, accounting for approximately 76.3% of the Group's total revenue for the year ended 31 December 2019[19] - Total revenue for the Group decreased from approximately RMB21.0 million in 2018 to RMB19.4 million in 2019, representing a decline of approximately 7.6%[19] - The Group's revenue for the year ended December 31, 2019, decreased by approximately RMB3.2 million, or 11.1%, to approximately RMB25.5 million compared to RMB28.7 million for the year ended December 31, 2018[35] - Revenue from male fertility IVD reagents, which accounted for approximately 76.3% of total revenue, was approximately RMB19.4 million, representing a decrease of approximately RMB1.6 million or 7.6% from RMB21.0 million in 2018[36] - Sales of parasite antibody detection reagents decreased by approximately RMB1.1 million, or 23.1%, from approximately RMB4.5 million in 2018[37] - Sales of auxiliary reproductive supplies and equipment decreased by approximately RMB648,000, or 33.0%, from approximately RMB2.0 million in 2018[38] - Direct sales revenue decreased from approximately RMB 14.1 million in 2018 to approximately RMB 13.0 million in 2019, a decline of RMB 1.1 million or 7.8%[82] - Revenue from sales to distributors decreased by approximately RMB 2.1 million or 14.6%, from approximately RMB 14.6 million in 2018 to approximately RMB 12.4 million in 2019[84] Operational Strategies - The Group focused on expanding its product portfolio and improving existing product offerings, as well as strengthening research and development capabilities[18] - The Group actively worked on expanding and consolidating its sales and distribution network during the year[18] - The Group maintained a stable employee base while cultivating and recruiting talented employees[18] - The Group emphasized international cooperation as part of its strategic initiatives[18] - The Group successfully developed a cost-efficient sales-centered philosophy aimed at serving the best interests of shareholders[18] - The Group's operational management methods were enhanced to improve execution capability and competitiveness[18] - The Group's strategy includes expanding the product portfolio and improving existing offerings, strengthening R&D capabilities, and developing auxiliary reproductive products[72] - The Group signed a non-legally binding memorandum of understanding for a joint venture in Hong Kong with an Australian fertility group to develop assisted reproductive technologies[73] Research and Development - The Group appointed Dr. Tian Long as a medical advisor to strengthen its R&D capacity in male fertility IVD reagents and auxiliary reproductive supplies[30] - Research and development expenses increased by approximately RMB288,000 or 19.5% to approximately RMB1.8 million for the year ended 31 December 2019, attributed to more research projects initiated[55] - Research and development expenses increased from RMB 1.5 million in 2018 to RMB 1.8 million in 2019, representing a growth of approximately RMB 288,000 or 19.5%[60] - The Group completed clinical trials for the sperm nuclear DNA integrity reagent and is planning to proceed with registration as of December 31, 2019[128] - The Group submitted Class II medical device registrations for improved products, including the "seminal plasma fructose quantitative assay kit" and "seminal plasma neutral alpha glucosidase quantitative assay kit" to the Guangdong Food and Drug Administration[129] Financial Performance - Gross profit decreased by approximately RMB3.7 million or 17.1% to approximately RMB17.9 million for the year ended 31 December 2019, compared to approximately RMB21.6 million for the year ended 31 December 2018[42] - The gross profit margin remained relatively stable at approximately 70.2% for the year ended 31 December 2019, compared to approximately 75.3% for the year ended 31 December 2018[43] - Selling and distribution expenses increased by approximately RMB2.7 million or 65.9% to approximately RMB6.8 million for the year ended 31 December 2019, primarily due to increased staff costs and marketing expenses[50] - Administrative expenses rose by approximately RMB4.0 million or 70.2% to approximately RMB9.7 million for the year ended 31 December 2019, mainly due to increased professional fees and staff costs[51] - The loss attributable to owners of the Company was approximately RMB284,000 for the year ended 31 December 2019, compared to approximately RMB459,000 for the year ended 31 December 2018[57] - Basic loss per share for the year was RMB0.07 cents, compared to RMB0.15 cents for the year ended 31 December 2018[58] - Other gains increased by approximately RMB670,000 or 413.6% to approximately RMB508,000 for the year ended 31 December 2019, mainly due to favorable foreign currency translation[45] Market Conditions - The decrease in male fertility IVD reagent sales is attributed to a decline in birth rates in the PRC from 10.94‰ in 2018 to 10.48‰ in 2019[36] - The birth rate in China decreased from 10.94‰ in 2018 to 10.48‰ in 2019, impacting sales of male fertility IVD reagents[67] - The Group anticipates growth in the male fertility IVD reagent market driven by rising infertility rates and supportive government policies[66] Human Resources - The number of sales and marketing personnel increased from 25 in 2018 to 30 in 2019 to support business expansion efforts[81] - The Group was unable to hire the expected number of suitable research and development personnel due to a limited supply of qualified candidates in the market as of December 31, 2019[128] - The Group has filled positions for two research and development personnel, two technicians, and two production workers as of December 31, 2019[128] Financial Management - Total cash and bank balances as of December 31, 2019, were approximately RMB 48.8 million, down from approximately RMB 54.8 million as of December 31, 2018[100] - Lease liabilities as of December 31, 2019, were approximately RMB 1.6 million, with a gearing ratio of approximately 2.3%[101] - Staff costs recognized in profit or loss amounted to approximately RMB 10.2 million for the year ended December 31, 2019, compared to RMB 6.6 million in 2018[103] - The Group did not make any material acquisitions or disposals of subsidiaries and affiliated companies during the year ended December 31, 2019[110] - The Group did not hold any significant investments as of December 31, 2019[111] - The Group's capital structure remained unchanged since the Listing, with equity attributable to owners amounting to approximately RMB 70.7 million as of December 31, 2019[102] - As of December 31, 2019, the Group had capital commitments of approximately RMB 78,000 for the acquisition of property, plant, and equipment, a decrease from RMB 329,000 in 2018[118] Corporate Governance - The company has independent non-executive directors responsible for supervising compliance and corporate governance matters[165] - The company has adopted and complied with the Corporate Governance Code during the year ended December 31, 2019[192] - The Board conducted reviews of the internal control system to ensure effectiveness and adequacy[193] - The company has a non-competition deed in place with controlling shareholders to prevent business competition[200] Use of Proceeds - The net proceeds from the Share Offer amounted to approximately HK$16.6 million after deducting underwriting fees and other expenses[130] - 41.5% of the net proceeds (HK$6.087 million) were allocated to developing new products and improving existing products, with actual expenditure of HK$4.710 million[133] - 27.3% of the net proceeds (HK$4.011 million) were used for expanding the sales network and enhancing marketing activities, with actual expenditure of HK$2.560 million[133] - 27.9% of the net proceeds (HK$4.100 million) were allocated to developing auxiliary reproductive supply business, with no actual expenditure reported[133] - 3.3% of the net proceeds (HK$0.481 million) were used for working capital, with actual expenditure of HK$0.281 million[133] - The remaining unused net proceeds as of December 31, 2019, were placed as bank balances with licensed banks in Hong Kong and PRC[136] - The company is not aware of any material change to the planned use of proceeds as of the date of the report[138]

Revenue and Market Performance - For the nine months ended September 30, 2019, the Group experienced a decrease in revenue from sales of male fertility IVD reagent products, attributed to a decline in birth rates and increased price sensitivity among customers [17]. - The Group anticipates continued support from the PRC Government for the biomedical industry, with growth in the male fertility IVD reagent market driven by rising infertility rates and the implementation of a universal two-child policy [17]. - The Group's major product line is male fertility IVD reagents, which are facing challenges due to market conditions [17]. - Revenue from male fertility IVD reagents decreased to RMB 14,517,000 for the nine months ended September 30, 2019, down 6.4% from RMB 15,508,000 in 2018 [144]. - Revenue from sales of biological reagents for the nine months ended September 30, 2019, was RMB 16,676,000, accounting for 90.5% of total revenue, while sales of auxiliary reproductive supplies and equipment contributed RMB 1,736,000 [144]. - The Group's total revenue for the nine months ended September 30, 2019, was RMB 18,412,000, a decrease of 12.8% compared to RMB 21,049,000 for the same period in 2018 [144]. Financial Performance - The Group's revenue decreased by approximately RMB2.6 million, or 12.4%, to approximately RMB18.4 million for the nine months ended 30 September 2019 compared to approximately RMB21.0 million for the same period in 2018 [24]. - The Group recorded a gross profit of approximately RMB13.2 million for the nine months ended 30 September 2019, a decrease of approximately RMB2.8 million, or approximately 17.5%, from approximately RMB16.0 million for the same period in 2018 [31]. - The gross profit margin remained relatively stable at approximately 71.6% for the nine months ended 30 September 2019, compared to approximately 75.8% for the same period in 2018 [32]. - Profit attributable to the owners of the company decreased to approximately RMB1.7 million for the nine months ended 30 September 2019, compared to approximately RMB4.0 million for the same period in 2018 [47]. - Basic earnings per share for the period was RMB0.43 cents, down from RMB1.32 cents for the nine months ended 30 September 2018 [47]. - The net profit attributable to the owners of the Company for the nine months ended September 30, 2019, was RMB 1,721,000, down 56.4% from RMB 3,951,000 in the previous year [122]. Expenses and Cost Management - Selling and distribution expenses increased from approximately RMB2.6 million to approximately RMB4.6 million, representing a growth of approximately RMB2.0 million or 76.9% during the period [41]. - Administrative expenses increased from approximately RMB3.4 million to approximately RMB6.4 million, representing an increase of approximately RMB3.0 million or 88.2% during the period [42]. - Research and development expenses increased from approximately RMB1.1 million for the nine months ended 30 September 2018 to approximately RMB1.2 million for the nine months ended 30 September 2019, representing an increase of approximately RMB66,000 or 6.0% [46]. - Total staff costs for the nine months ended September 30, 2019, were RMB 6,539,000, an increase of 37% compared to RMB 4,772,000 in the same period of 2018 [162]. Strategic Initiatives - The Group's strategy includes expanding the product portfolio, enhancing research and development capabilities, and consolidating the sales and distribution network [18]. - The Group aims to improve product competitiveness through increased focus on research and development and market promotion efforts [18]. - The Group is committed to developing its auxiliary reproductive supply business as part of its growth strategy [18]. - The Group plans to develop and sell auxiliary reproductive products in the PRC and overseas markets, collaborating with a Canadian manufacturer to enhance male fertility functions [23]. Corporate Governance and Compliance - The Company has adopted and complied with the Corporate Governance Code during the relevant period [110]. - The Board conducted reviews of the internal control system to ensure effectiveness and adequacy [111]. - All Directors confirmed full compliance with the Required Standard for securities transactions during the relevant period [112]. - The Company appointed Ever-Long Securities Company Limited as the new compliance adviser effective from 31 May 2019 [102]. Shareholder Information - As of September 30, 2019, Mr. Zhang Shuguang held 240,000,000 shares, representing 60.0% of the total shareholding [83]. - The total number of shares in issue as of September 30, 2019, was 400,000,000 [85]. - The company’s shares are controlled by Mr. Zhang Shuguang and Mr. Chang Yim Yang, who hold equity interests indirectly through their respective companies [126]. Other Financial Information - The company recognized a gain on the disposal of property, plant, and equipment of RMB 10,000 for the nine months ended September 30, 2019, compared to no gains in the same period of 2018 [155]. - The total impairment losses reversed for the nine months ended September 30, 2019, were RMB 534,000, compared to RMB 129,000 in the same period of 2018, indicating a substantial increase of 314% [157]. - The company incurred research and development expenses of RMB 1,157,000 for the nine months ended September 30, 2019 [122].

Revenue and Profitability - For the six months ended June 30, 2019, the Group experienced a decrease in revenue from sales of male fertility IVD reagent products, which was the major product, attributed to a decrease in birth rate and increased price sensitivity among customers[17]. - The Group's revenue decreased by approximately RMB1.7 million or 12.9%, to approximately RMB11.6 million for the six months ended 30 June 2019, compared to approximately RMB13.4 million for the same period in 2018[21]. - Revenue from male fertility IVD reagents, which accounted for approximately 82.7% of total revenue, decreased by approximately RMB1.2 million or 11.4% to approximately RMB9.6 million for the six months ended 30 June 2019[21]. - The Group recorded a profit of approximately RMB 223,000 for the six months ended June 30, 2019, a decrease from approximately RMB 2.0 million for the same period in 2018[41]. - Excluding non-recurring listing expenses, the Group recorded a profit before tax of approximately RMB 670,000 for the six months ended 30 June 2019, down from approximately RMB 6.0 million for the same period in 2018[42]. - Basic earnings per share for the six months ended June 30, 2019, was RMB 0.06, down from RMB 0.68 in the same period of 2018[150]. Expenses and Financial Performance - Gross profit decreased by approximately RMB1.6 million or 16.0% to approximately RMB8.5 million for the six months ended 30 June 2019, with a gross profit margin of approximately 72.6%[26][27]. - Selling and distribution expenses increased by approximately RMB1.3 million or 82.6% to approximately RMB2.9 million for the six months ended 30 June 2019, primarily due to increased staff costs and marketing expenses[35]. - Administrative expenses rose by approximately RMB2.3 million or 105.8% to approximately RMB4.5 million for the six months ended 30 June 2019, driven by higher audit fees and staff costs[36]. - Research and development expenses increased from approximately RMB 699,000 for the six months ended 30 June 2018 to approximately RMB 832,000 for the six months ended 30 June 2019, representing an increase of approximately RMB 133,000 or 19.0%[40]. - The company incurred net cash used in operating activities of RMB 7,767,000 for the six months ended June 30, 2019, compared to a net cash inflow of RMB 1,297,000 in the same period of 2018[156]. Strategic Focus and Development - The development strategy includes expanding the product portfolio, improving existing offerings, strengthening R&D capabilities, and consolidating the sales and distribution network[18]. - The Group's strategic focus includes enhancing R&D capabilities, expanding the product portfolio, and increasing market promotion efforts to capture market opportunities[19]. - The Group has continued the final stage of clinical trials for in vitro diagnostic reagents for sperm nuclear DNA integrity, with three independent hospitals involved[54]. - The Group manufactured a prototype of semen biochemical immunoassay equipment, which is currently undergoing debugging[54]. - Three newly developed products are undergoing final clinical evaluation and trials, with plans to proceed with registration within the year[66]. Government Support and Market Conditions - The Group anticipates continued support from the PRC Government for the biomedical industry, driven by rising infertility rates, acceptance of assisted reproductive treatments, and favorable government policies[17]. - The decrease in sales of auxiliary reproductive supplies and equipment was approximately RMB241,000, primarily due to reduced demand for automatic enzyme-linked immunologic workstations[22]. Corporate Governance and Compliance - The Board is committed to high corporate governance standards, which are essential for safeguarding shareholder interests and enhancing corporate value[135]. - The Company has complied with the Corporate Governance Code during the relevant period, ensuring transparency and accountability[132]. - The Audit Committee consists of three independent non-executive Directors, ensuring oversight of financial reporting and internal controls[141]. - The Company has made adequate disclosures in accordance with GEM Listing Rules and other legal requirements[146]. Financial Position and Assets - As of June 30, 2019, the Group's total cash and bank balances were approximately RMB 46.1 million, a decrease from approximately RMB 54.8 million as of December 31, 2018, primarily due to daily operating expenses[63]. - Total assets less current liabilities as of June 30, 2019, amounted to RMB 71,902,000, slightly up from RMB 71,451,000 as of December 31, 2018[152]. - Non-current assets as of June 30, 2019, totaled RMB 14,448,000, an increase from RMB 13,667,000 as of December 31, 2018[151]. - The Group reported a net current assets value of RMB 57,454,000 as of June 30, 2019, slightly down from RMB 57,784,000 as of December 31, 2018[151]. Shareholder Information - The interests of Mr. Zhang Shuguang, a Director, include 240,000,000 shares, representing 60.0% of the total shares issued as of June 30, 2019[107]. - The total number of shares in issue as of June 30, 2019, was 400,000,000[107]. - As of June 30, 2019, the substantial shareholders include Crystal Grant and Ever Charming, each holding 240,000,000 shares, representing 60.0% of the total shareholding[116]. - Gallizul Global Investments and Huang Yan each hold 36,000,000 shares, accounting for 9.0% of the total shareholding[116]. Accounting Policies and Financial Reporting - The financial statements have been prepared in accordance with applicable Hong Kong Financial Reporting Standards (HKFRSs) and the disclosure requirements of the Hong Kong Companies Ordinance[166]. - The unaudited condensed consolidated financial statements are presented in Renminbi (RMB), which is the functional currency of the Company and its subsidiaries[160]. - The Group has not early adopted any new and revised HKFRSs that have been issued but not yet effective in the current accounting period[169]. - The financial statements have been prepared under the historical cost basis[174]. - The Group has chosen not to separate non-lease components from lease components, treating them as a single lease component[191].

Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公 司 (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號: 8622 FIRST QUARTERLY REPORT 第一季度業績報告 20 19 Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公 司 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than ...

Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公 司 (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號: 8622 ANNUAL REPORT 年 報 20 18 Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公 司 ANNUAL REPORT 2018 年報 Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公 This Report, for which the Directors (the "Directors") of Huakang Biomedical Holdings Company Limited (the "Company", and together with its subsidiaries, the "Group", "we" or "our") collectively ...